ICU Medical (NASDAQ:ICUI) Cut to Hold at StockNews.com

ICU Medical (NASDAQ:ICUI) was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued on Saturday.

Several other brokerages have also weighed in on ICUI. Raymond James lowered their price objective on ICU Medical from $197.00 to $187.00 and set a “strong-buy” rating for the company in a research report on Friday. KeyCorp decreased their price target on ICU Medical from $209.00 to $191.00 and set an “overweight” rating on the stock in a research note on Monday, April 21st. Finally, Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a research report on Tuesday, April 8th. Two research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $192.67.

ICU Medical Price Performance

ICU Medical stock opened at $138.30 on Friday. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75. The company has a 50-day moving average price of $140.67 and a 200 day moving average price of $154.99. ICU Medical has a 12-month low of $100.91 and a 12-month high of $196.26. The stock has a market cap of $3.40 billion, a P/E ratio of -30.26 and a beta of 0.87.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.72 earnings per share for the quarter, beating the consensus estimate of $1.23 by $0.49. The business had revenue of $599.49 million during the quarter, compared to analysts’ expectations of $574.15 million. ICU Medical had a negative net margin of 4.74% and a positive return on equity of 5.05%. The business’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.96 EPS. Sell-side analysts anticipate that ICU Medical will post 4.11 earnings per share for the current year.

Hedge Funds Weigh In On ICU Medical

Hedge funds have recently made changes to their positions in the stock. Arizona State Retirement System raised its position in ICU Medical by 1.0% in the fourth quarter. Arizona State Retirement System now owns 6,730 shares of the medical instruments supplier’s stock valued at $1,044,000 after purchasing an additional 65 shares during the period. Huntington National Bank grew its stake in shares of ICU Medical by 6.2% in the fourth quarter. Huntington National Bank now owns 1,402 shares of the medical instruments supplier’s stock valued at $218,000 after buying an additional 82 shares in the last quarter. Equitable Trust Co. raised its holdings in shares of ICU Medical by 1.6% in the 4th quarter. Equitable Trust Co. now owns 5,297 shares of the medical instruments supplier’s stock valued at $822,000 after buying an additional 84 shares during the period. Xponance Inc. raised its holdings in shares of ICU Medical by 5.3% in the 1st quarter. Xponance Inc. now owns 1,714 shares of the medical instruments supplier’s stock valued at $238,000 after buying an additional 86 shares during the period. Finally, LPL Financial LLC raised its holdings in shares of ICU Medical by 2.0% in the 4th quarter. LPL Financial LLC now owns 4,816 shares of the medical instruments supplier’s stock valued at $747,000 after buying an additional 93 shares during the period. Hedge funds and other institutional investors own 96.10% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.